{"id":139454,"date":"2026-08-03T01:57:14","date_gmt":"2026-08-03T01:57:14","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/139454\/"},"modified":"2026-08-03T01:57:14","modified_gmt":"2026-08-03T01:57:14","slug":"novo-nordisk-nvo-trial-setback-hits-sentiment-is-the-stock-still-cheap-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/139454\/","title":{"rendered":"Novo Nordisk (NVO) Trial Setback Hits Sentiment, Is The Stock Still Cheap?"},"content":{"rendered":"\n

Find winning stocks<\/a> in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE. <\/p>\n

Trial setback puts focus on Novo Nordisk stock <\/p>\n

Novo Nordisk (NYSE:NVO) is under fresh scrutiny after the ZEUS phase 3 trial for heart drug candidate ziltivekimab failed to reduce major adverse cardiovascular events versus placebo, prompting a share price drop. <\/p>\n

See our latest analysis for Novo Nordisk.<\/a> <\/p>\n

The ZEUS result comes after a tougher start to the year for Novo Nordisk, with the share price down 10.14% year to date and the latest 1 day move falling 8.78%. However, the 90 day share price return is up 7.29% and the 1 year total shareholder return is slightly positive at 0.92%. This suggests recent momentum has faded compared with longer term results. <\/p>\n

If this setback has you reassessing healthcare exposure, it can help to widen the opportunity set and see which other companies are gaining attention through 41 healthcare AI stocks<\/a> <\/p>\n

Novo Nordisk now trades at a small 3% discount to average analyst targets, yet internal estimates suggest a much steeper 52% gap to intrinsic value. Is the latest trial disappointment enough to justify that caution? <\/p>\n

Most Popular Narrative: 54% Undervalued <\/p>\n

The most followed narrative on Novo Nordisk pitches a fair value of $102.97 against the last close of $47.08. That gap relies heavily on a handful of potential growth drivers. <\/p>\n

Catalysts <\/p>\n

Recent success in a phase IIIa trial showed once-daily doses of oral semaglutide demonstrated a statistically significant and superior reduction in HbA1c by 0.83% versus placebo at 26 weeks for adolescents with Type II diabetes. Based on the study data, NVO intends to seek regulatory approval for oral semaglutide in adolescents aged 10 to 17 with T2D for both Rybelsus and oral Ozempic in the U.S. and the EU in the second half of the year. Due to a lack of effective treatment options for adolescents with T2D, NVO will benefit greatly from having the only approved treatment for the 20.9 million adolescents with T2D. As the only player in this market NVO would see increased revenue growth and margin expansion, restoring much of the growth narrative that has softened in recent years. <\/p>\n

Read the complete narrative.<\/a> <\/p>\n

Want to understand why this narrative sees Novo Nordisk at more than double today’s price? It leans on ambitious revenue, margin and valuation assumptions. Curious which financial levers matter most here and how they stack up against the company’s recent track record and sector averages? The full narrative sets out those projections in detail. <\/p>\n

Result: Fair Value of $102.97 (UNDERVALUED) <\/p>\n

Have a read of the narrative in full and understand what’s behind the forecasts.<\/a> <\/p>\n

However, this bullish Novo Nordisk narrative could be knocked off course if GLP-1 growth projections prove too optimistic or if regulatory decisions on approvals and compounding shift. <\/p>\n

Find out about the key risks to this Novo Nordisk narrative.<\/a> <\/p>\n

Next Steps <\/p>\n

With both risks and rewards in play for Novo Nordisk, this is a moment to move quickly and test the numbers yourself. To see how those trade offs look when set out side by side, review the 3 key rewards and 4 important warning signs<\/a>. <\/p>\n

Looking for more investment ideas beyond Novo Nordisk? <\/p>\n

Do not stop your research with Novo Nordisk. Broaden your watchlist now so you are not relying on a single stock or theme for future decisions. <\/p>\n

Target dependable income by reviewing companies that qualify as 9 dividend fortresses<\/a> and see which payouts look most consistent with their underlying fundamentals. <\/p>\n

Hunt for potential bargains by checking companies flagged as 55 high quality undervalued stocks<\/a> where quality metrics and current pricing appear out of sync. <\/p>\n

Prioritize stability by focusing on businesses highlighted in the 81 resilient stocks with low risk scores<\/a> and see which balance sheets and risk profiles stand out. <\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. <\/p>\n

Companies discussed in this article include NVO<\/a>. <\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…\n","protected":false},"author":2,"featured_media":139455,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[1146,272],"class_list":["post-139454","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-intrinsic-value","tag-novo-nordisk"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117029099661540052","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/139454","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=139454"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/139454\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/139455"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=139454"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=139454"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=139454"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}